NEWS Release

Manufacturing and Option Agreement Remains Unchanged

Date: June 8, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

As Novartis AG (NYSE:NVS) announced yesterday that Sandoz, a Novartis company, has acquired Sabex Holdings Ltd., International Wex Technologies Inc. ("Wex" or the "Company") is pleased to announce that the Manufacturing and Option Agreement the Company has with Sabex will remain unchanged and Sabex will continue to manufacture Wex's clinical lots. With this acquisition Sandoz will now hold the first right of refusal to acquire an exclusive license for Wex's injectable products in Canada.

The Company looks forward to continued work with Sabex as implementation of Wex's global strategy continues and work towards receiving market approval for its products.

International Wex Technologies Inc. is a publicly listed neuro-bioscience company (WXI) focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Don Evans or Gordon Stanley, Corporate Communications at 604-683-8880 or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.